Moderna's $2B offering; AstraZeneca-Amgen and Biokin chalk up Phase 3 wins
Plus news about Takeda China and ProFound. Moderna's $2B offering: The mRNA biotech will offer convertible senior notes for the "flexibility to invest" in growing its oncology business and repay debt ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.